A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting.
Amir Iravani, a nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program and vice chair of clinical research in the department of nuclear medicine and theranostics.
